References
- 1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167-74. doi: 10.1097/CCM.0b013e31827c09f8.
- 2. Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respiratory Med. 2014;2:380-6. doi: 10.1016/s2213-2600(14)70061-x.
- 3. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10. doi: 10.1001/jama.2016.0287.
- 4. Copotoiu SM, Copotoiu R. Much Ado About the New Definitions of Sepsis. J Crit Care Med. 2016;2:67-72. doi: 10.1515/jccm-2016-0015.
- 5. Rawal G, Kumar R, Yadav S, Singh A. Anemia in Intensive Care: A review of Current Concepts. J Crit Care Med. 2016;2:109-14. doi: 10.1515/jccm-2016-0017.
- 6. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129:290-295. doi: 10.1016/j.thromres.2011.10.013.
- 7. Levi M. The coagulant response in sepsis and inflammation. Hamostaseologie 2010;30:10-2.
- 8. Allen KS, Sawheny E, Kinasewitz GT. Anticoagulant modulation of inflammation in severe sepsis. World J Crit Care Med. 2015;4:105-15. doi: 10.5492/wjccm.v4.i2.105.
- 9. Wiersinga WJ, Levi M, van der Poll T. Coagulation in Sepsis. In: Abraham E, Singer M, editors. Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. p. 273-85.
- 10. Camicia G, Pozner R, de Larranaga G. Neutrophil extracellular traps in sepsis. Shock. 2014;42:286-94. doi: 10.1097/SHK.0000000000000221.
- 11. Pawlinski R, Mackman N. Cellular sources of tissue factor in endotoxemia and sepsis. Thromb Res. 2010;125(Suppl1):S70-S73. doi: 10.1016/j.thromres.2010.01.042.
- 12. Mackman N. The many faces of tissue factor. J Thromb Haemost. 2009;7(Suppl1):136–9. doi: 10.1111/j.1538-7836.2009.03368.x.
- 13. Taylor FB, Chang AC, Peer G, et al. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood. 1998;91:1609-15.
- 14. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med. 2003;167:1200-9. doi: 10.1164/rccm.200204-287OC.
- 15. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost. 2001;27:639-51. doi: 10.1055/s-2001-18868.
- 16. Sovershaev MA, Lind KF, Devold H, et al. No evidence for the presence of tissue factor in high-purity preparations of immunologically isolated eosinophils. J Thromb Haemost. 2008;6:1742-9. doi: 10.1111/j.1538-7836.2008.03105.x.
- 17. Egorina EM, Sovershaev MA, Olsen JO, Osterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood. 2008;111:1208-16. doi: 10.1182/blood-2007-08-107698.
- 18. Rondina MT, Schwertz H, Harris ES, et al. The septic milieu triggers expression of spliced tissue factor mRNA in human platelets. J Thromb Haemost. 2011;9:748-58. doi: 10.1111/j.1538-7836.2011.04208.x.
- 19. Liu D, Zhang D, Scafidi J, et al. C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood. 2005;105:2350-5. doi: 10.1182/blood-2004-05-1963.
- 20. Lupu C, Westmuckett AD, Peer G, et al. Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis. Am J Pathol. 2005;167:1161-72. doi: 10.1016/s0002-9440(10)61204-7.
- 21. Szotowski B, Antoniak S, Rauch U. Alternatively spliced tissue factor: a previously unknown piece in the puzzle of hemostasis. Trends Cardiovasc Med. 2006;16:177-82. doi: 10.1016/j.tcm.2006.03.005.
- 22. van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care. 2008;12(Suppl 6):S3. doi: 10.1186/cc7026.
- 23. Souza AC, Yuen PS, Star RA. Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int. 2015;87:1100-8. doi: 10.1038/ki.2015.26.
- 24. Reid VL, Webster NR. Role of microparticles in sepsis. Br J Anaesth. 2012;109:503-13. doi: 10.1093/bja/aes321.
- 25. Zafrani L, Gerotziafas G, Byrnes C, et al. Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release. Am J Respir Crit Care Med. 2012;185:744-55. doi: 10.1164/rccm.201109-1686OC.
- 26. Woei AJFJ, van der Starre WE, Tesselaar ME, et al. Procoagulant tissue factor activity on microparticles is associated with disease severity and bacteremia in febrile urinary tract infections. Thromb Res. 2014;133:799-803. doi: 10.1016/j.thromres.2014.03.007.
- 27. Forest A, Pautas E, Ray P, et al. Circulating microparticles and procoagulant activity in elderly patients. J Gerontol A Biol Sci Med Sci. 2010;65:414-20. doi: 10.1093/gerona/glp187.
- 28. Mooberry MJ, Bradford R, Hobl EL, et al. Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia. J Thromb Haemost. 2016;14:1031-42. doi: 10.1111/jth.13285.
- 29. Levi M, Poll T. Coagulation in patients with severe sepsis. Semin Thromb Hemost. 2015;41:9-15. doi: 10.1055/s-0034-1398376.
- 30. Yaguchi A, Lobo FL, Vincent JL, Pradier O. Platelet function in sepsis. J Thromb Haemost. 2004;2:2096-102. doi: 10.1111/j.1538-7836.2004.01009.x.
- 31. de Stoppelaar SF, van ’t Veer C, Claushuis TAM, et al. Thrombocytopenia impairs host defense in gram-negative pneumonia–derived sepsis in mice. Blood. 2014;124:3781-90. doi: 10.1182/blood-2014-05-573915.
- 32. Xiang B, Zhang G, Guo L, et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun. 2013;4:2657. doi: 10.1038/ncomms3657.
- 33. Sonego F, Castanheira FV, Ferreira RG, et al. Paradoxical Roles of the Neutrophil in Sepsis: Protective and Deleterious. Front Immunol. 2016;7:155. doi: 10.3389/fimmu.2016.00155.
- 34. Czaikoski PG, Mota JM, Nascimento DC, et al. Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical Sepsis. PloS One. 2016;11:e0148142. doi: 10.1371/journal.pone.0148142.
- 35. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007;13:463-9. doi: 10.1038/nm1565.
- 36. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PloS One. 2012;7:e45427. doi: 10.1371/journal.pone.0045427.
- 37. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost. 2008;34:459-68. doi: 10.1055/s-0028-1092876.
- 38. Levi M, van der Poll T, Schultz M. New insights into pathways that determine the link between infection and thrombosis. Neth J Med. 2012;70:114-20.
- 39. Levi M. Antithrombin in sepsis revisited. Crit Care. 2005;9:624-5. doi: 10.1186/cc3819.
- 40. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood. 2000;95:1117-23.
- 41. King EG, Bauza GJ, Mella JR, Remick DG. Pathophysiologic mechanisms in septic shock. Lab Invest. 2014;94:4-12. doi: 10.1038/labinvest.2013.110.
- 42. Levi M, Dorffler-Melly J, Reitsma P, et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003;101:4823-7. doi: 10.1182/blood-2002-10-3254.
- 43. Tang H, Ivanciu L, Popescu N, et al. Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am J Pathol. 2007;171:1066-77. doi: 10.2353/ajpath.2007.070104.
- 44. Draxler DF, Medcalf RL. The fibrinolytic system-more than fibrinolysis? Transfus Med Rev. 2015;29:102-9. doi: 10.1016/j.tmrv.2014.09.006.
- 45. Fourrier F. Severe sepsis, coagulation, and fibrinolysis: dead end or one way? Crit Care Med. 2012;40:2704-8. doi: 10.1097/CCM.0b013e318258ff30.
- 46. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest. 2005;128:2864-75. doi: 10.1378/chest.128.4.2864.
- 47. Binette TM, Taylor FB, Peer G, Bajzar L. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood. 2007;110:3168-75. doi: 10.1182/blood-2007-03-078824.
- 48. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res. 2006;118:205-12. doi: 10.1016/j.thromres.2005.06.007.
- 49. Prakash S, Verghese S, Roxby D, et al. Changes in fibrinolysis and severity of organ failure in sepsis: a prospective observational study using point-of-care test--ROTEM. J Crit Care. 2015;30:264-70. doi: 10.1016/j.jcrc.2014.10.014.
- 50. Hayakawa M, Sawamura A, Gando S, et al. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res. 2012;130:906-13. doi: 10.1016/j.thromres.2012.01.015.
- 51. Zeerleder S, Schroeder V, Lammle B, et al. Factor XIII in severe sepsis and septic shock. Thromb Res. 2007;119:311-8. doi: 10.1016/j.thromres.2006.02.003.
- 52. de Jonge E, Friederich PW, Vlasuk GP, et al. Activation of Coagulation by Administration of Recombinant Factor VIIa Elicits Interleukin 6 (IL-6) and IL-8 Release in Healthy Human Subjects. Clin Diagn Lab Immunol. 2003;10:495-97. doi: 10.1128/cdli.10.3.495-497.2003.
- 53. Fiusa MM, Carvalho-Filho MA, Annichino-Bizzacchi JM, De Paula EV. Causes and consequences of coagulation activation in sepsis: an evolutionary medicine perspective. BMC Med. 2015;13:105. doi: 10.1186/s12916-015-0327-2.
- 54. Kapur R, Zufferey A, Boilard E, Semple JW. Nouvelle cuisine: platelets served with inflammation. J Immunol. 2015;194:5579-87. doi: 10.4049/jimmunol.1500259.
- 55. Carestia A, Rivadeneyra L, Romaniuk MA, et al. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb Haemost. 2013;110:1035-45. doi: 10.1160/th13-02-0174.
- 56. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemos. 2006;32(Suppl1):49-60. doi: 10.1055/s-2006-939554.
- 57. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis. 2001;183:1815-8. doi: 10.1086/320723.
- 58. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood. 2000;95:1124-9.
- 59. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2:67. doi: 10.1186/s40560-014-0065-0.
- 60. Georgescu AM, Szederjesi J, Voidăzan S, et al. Soluble urokinase-type plasminogen activator receptor (suPAR) – a possible biomarker for bacteremia in sepsis / Forma solubilă a receptorului pentru activatorul de plasminogen de tip urokinază (suPAR) – un biomarker posibil pentru bacteriemie în sepsis. Rev Romana Med Lab. 2015;23:59-73. doi: 10.1515/rrlm-2015-0002.
- 61. Szederjesi J, Almasy E, Lazar A, et al. An Evaluation of Serum Procalcitonin and C-Reactive Protein Levels as Diagnostic and Prognostic Biomarkers of Severe Sepsis. J Crit Care Med. 2015;1:143-7. doi: 10.1515/jccm-2015-0022.
- 62. Dhainaut JF, Shorr AF, Macias WL, et al. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med. 2005;33:341-8.
- 63. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366:2055-64. doi: 10.1056/NEJMoa1202290.
- 64. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869-78.
- 65. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238-47. doi: 10.1001/jama.290.2.238.
- 66. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33. doi: 10.1111/j.1538-7836.2004.00955.x.
- 67. Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006;4:90-7. doi: 10.1111/j.1538-7836.2005.01697.x.